Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise - PubMed (original) (raw)
Clinical Trial
. 1999 May;33(6):1567-72.
doi: 10.1016/s0735-1097(99)00048-0.
Affiliations
- PMID: 10334425
- DOI: 10.1016/s0735-1097(99)00048-0
Free article
Clinical Trial
Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise
J G Warner Jr et al. J Am Coll Cardiol. 1999 May.
Free article
Abstract
Objectives: The aim of the study was to test the hypothesis that angiotensin II (Ang II) blockade would improve exercise tolerance in patients with diastolic dysfunction and a marked increase in systolic blood pressure (SBP) during exercise.
Background: Diastolic dysfunction may be exacerbated during exercise, especially if there is a marked increase in SBP. Angiotensin II may contribute to the hypertensive response to exercise and impair diastolic performance.
Methods: We performed a randomized, double-blind, placebo-controlled, crossover study of two weeks of losartan (50 mg q.d.) on exercise tolerance and quality of life. The subjects were 20 patients, mean age 64 +/- 10 years with normal left ventricular systolic function (EF >50%), no ischemia on stress echocardiogram, mitral flow velocity E/A <1, normal resting SBP (<150 mm Hg), and a hypertensive response to exercise (SBP >200 mm Hg). Exercise echocardiograms (Modified Bruce Protocol) and the Minnesota Living With Heart Failure questionnaire were administered at baseline, and after each two-week treatment period, separated by a two-week washout period.
Results: Resting blood pressure (BP) was unaltered by placebo or losartan. During control, patients were able to exercise for 11.3 +/- 2.5 (mean +/- SD) min, with a peak exercise SBP of 226 +/- 24 mm Hg. After two weeks of losartan, baseline BP was unaltered, but peak SBP during exercise decreased to 193 +/- 27 mm Hg (p < 0.05 vs. baseline and placebo), and exercise time increased to 12.3 +/- 2.6 min (p < 0.05 vs. baseline and placebo). With placebo, there was no improvement in exercise duration (11.0 +/- 2.0 min) or peak exercise SBP (217 +/- 26 mm Hg). Quality of life improved with losartan (18 +/- 22, p < 0.05) compared to placebo (22 +/- 26).
Conclusions: In patients with Doppler evidence of diastolic dysfunction at rest and a hypertensive response to exercise, Ang II receptor blockade blunts the hypertensive response to exercise, increases exercise tolerance and improves quality of life.
Similar articles
- Effect of losartan and hydrochlorothiazide on exercise tolerance in exertional hypertension and left ventricular diastolic dysfunction.
Little WC, Zile MR, Klein A, Appleton CP, Kitzman DW, Wesley-Farrington DJ. Little WC, et al. Am J Cardiol. 2006 Aug 1;98(3):383-5. doi: 10.1016/j.amjcard.2006.01.106. Epub 2006 Jun 12. Am J Cardiol. 2006. PMID: 16860028 Clinical Trial. - Effect of candesartan and verapamil on exercise tolerance in diastolic dysfunction.
Little WC, Wesley-Farrington DJ, Hoyle J, Brucks S, Robertson S, Kitzman DW, Cheng CP. Little WC, et al. J Cardiovasc Pharmacol. 2004 Feb;43(2):288-93. doi: 10.1097/00005344-200402000-00019. J Cardiovasc Pharmacol. 2004. PMID: 14716219 Clinical Trial. - Adding thiazide to a renin-angiotensin blocker improves left ventricular relaxation and improves heart failure in patients with hypertension.
Ito H, Ishii K, Kihara H, Kasayuki N, Nakamura F, Shimada K, Fukuda S, Iwakura K, Yoshikawa J; Effect of ARB/Diuretics on Diastolic Function in Patients with Hypertension (EDEN) trial investigators. Ito H, et al. Hypertens Res. 2012 Jan;35(1):93-9. doi: 10.1038/hr.2011.169. Epub 2011 Oct 20. Hypertens Res. 2012. PMID: 22011686 Free PMC article. Clinical Trial. - Left ventricular diastolic dysfunction in hypertension.
Fouad-Tarazi FM. Fouad-Tarazi FM. Curr Opin Cardiol. 1994 Sep;9(5):551-60. doi: 10.1097/00001573-199409000-00008. Curr Opin Cardiol. 1994. PMID: 7987034 Review. - Diastolic dysfunction as a cause of exercise intolerance.
Little WC, Kitzman DW, Cheng CP. Little WC, et al. Heart Fail Rev. 2000 Dec;5(4):301-6. doi: 10.1023/a:1026503028065. Heart Fail Rev. 2000. PMID: 11498643 Review.
Cited by
- Possible Mechanisms for Adverse Cardiac Events Caused by Exercise-Induced Hypertension in Long-Distance Middle-Aged Runners: A Review.
Kim YJ, Park KM. Kim YJ, et al. J Clin Med. 2024 Apr 10;13(8):2184. doi: 10.3390/jcm13082184. J Clin Med. 2024. PMID: 38673457 Free PMC article. Review. - Prognostic Implications of Exercise-Induced Hypertension in Adults With Repaired Coarctation of Aorta.
Egbe AC, Miranda WR, Jain CC, Borlaug BA, Connolly HM. Egbe AC, et al. Hypertension. 2022 Dec;79(12):2796-2805. doi: 10.1161/HYPERTENSIONAHA.122.19735. Epub 2022 Oct 12. Hypertension. 2022. PMID: 36252107 Free PMC article. - Renin-Angiotensin System Blockade Is Associated with Exercise Capacity, Sympathetic Activity, and Endothelial Function in Patients with Chronic Kidney Disease.
Jeong JH, Sprick JD, DaCosta D, Quyyumi AA, Park J. Jeong JH, et al. Kidney Blood Press Res. 2022;47(2):103-112. doi: 10.1159/000520760. Epub 2021 Nov 10. Kidney Blood Press Res. 2022. PMID: 34758473 Free PMC article. - Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N, Manoharan K, Davies C, Lumbers RT. Martin N, et al. Cochrane Database Syst Rev. 2021 May 22;5(5):CD012721. doi: 10.1002/14651858.CD012721.pub3. Cochrane Database Syst Rev. 2021. PMID: 34022072 Free PMC article. - Exercise-induced hypertension is associated with angiotensin II activity and total nitric oxide.
Kim CH, Park Y, Chun MY, Kim YJ. Kim CH, et al. Medicine (Baltimore). 2020 Jul 2;99(27):e20943. doi: 10.1097/MD.0000000000020943. Medicine (Baltimore). 2020. PMID: 32629698 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous